$BRNS
Barinthus Biotherapeutics PLC

2021 Q4 Form 10-Q Financial Statement

#000110465921137646 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $268.0K $19.00K $3.251M
YoY Change -24.14% -99.42%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $25.12M $2.878M $977.0K
YoY Change 238.44% 194.58%
% of Gross Profit
Research & Development $20.37M $4.371M $3.702M
YoY Change 694.03% 18.07%
% of Gross Profit
Depreciation & Amortization $321.0K $85.00K $152.0K
YoY Change 469.15% -44.08%
% of Gross Profit
Operating Expenses $45.49M $5.555M $4.679M
YoY Change 355.47% 18.72%
Operating Profit -$5.536M -$1.428M
YoY Change 287.68%
Interest Expense $3.537M $0.00 $969.0K
YoY Change -413.54% -100.0%
% of Operating Profit
Other Income/Expense, Net $4.333M $959.0K $1.628M
YoY Change 1207.09% -41.09%
Pretax Income -$51.14M -$4.577M $200.0K
YoY Change 390.29% -2388.5%
Income Tax -$28.00K -$7.000K $0.00
% Of Pretax Income 0.0%
Net Earnings -$50.87M -$4.557M $158.0K
YoY Change 386.51% -2984.18%
Net Earnings / Revenue -18979.48% -23984.21% 4.86%
Basic Earnings Per Share -$0.13 $0.02
Diluted Earnings Per Share -$1.964M -$0.13 $0.01
COMMON SHARES
Basic Shares Outstanding 34.85M 34.84M 7.937M
Diluted Shares Outstanding 34.84M 15.87M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $214.1M $233.9M
YoY Change
Cash & Equivalents $214.1M $233.9M $29.63M
Short-Term Investments
Other Short-Term Assets $995.0K $482.0K
YoY Change 3331.03%
Inventory
Prepaid Expenses $4.612M $5.639M
Receivables $20.00K $42.00K
Other Receivables $6.934M $5.890M
Total Short-Term Assets $226.8M $246.0M
YoY Change 373.4%
LONG-TERM ASSETS
Property, Plant & Equipment $1.829M $1.033M
YoY Change 190.78%
Goodwill $12.63M
YoY Change
Intangibles $31.43M
YoY Change
Long-Term Investments
YoY Change
Other Assets $804.0K $779.0K
YoY Change
Total Long-Term Assets $53.95M $10.59M
YoY Change 1851.18%
TOTAL ASSETS
Total Short-Term Assets $226.8M $246.0M
Total Long-Term Assets $53.95M $10.59M
Total Assets $280.7M $256.6M
YoY Change 454.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.419M $1.337M
YoY Change -48.17%
Accrued Expenses $8.398M $4.839M
YoY Change
Deferred Revenue $182.0K $196.0K
YoY Change -25.71%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $159.0K
YoY Change
Total Short-Term Liabilities $11.16M $6.372M
YoY Change 46.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.911M $7.728M
YoY Change
Total Long-Term Liabilities $8.911M $7.728M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $11.16M $6.372M
Total Long-Term Liabilities $8.911M $7.728M
Total Liabilities $28.15M $14.10M
YoY Change -47.68%
SHAREHOLDERS EQUITY
Retained Earnings -$108.6M -$93.47M
YoY Change 88.12%
Common Stock $1.000K $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $252.1M $242.0M
YoY Change
Total Liabilities & Shareholders Equity $280.7M $256.6M
YoY Change 454.05%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$50.87M -$4.557M $158.0K
YoY Change 386.51% -2984.18%
Depreciation, Depletion And Amortization $321.0K $85.00K $152.0K
YoY Change 469.15% -44.08%
Cash From Operating Activities -$7.972M -$2.018M -$6.132M
YoY Change 62.82% -67.09%
INVESTING ACTIVITIES
Capital Expenditures -$424.0K -$128.0K -$98.00K
YoY Change 117.69% 30.61%
Acquisitions
YoY Change
Other Investing Activities -$11.77M
YoY Change
Cash From Investing Activities -$12.19M -$128.0K -$98.00K
YoY Change 6158.66% 30.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.000K -1.387M 24.95M
YoY Change -99.95% -105.56%
NET CHANGE
Cash From Operating Activities -7.972M -2.018M -6.132M
Cash From Investing Activities -12.19M -128.0K -98.00K
Cash From Financing Activities 9.000K -1.387M 24.95M
Net Change In Cash -20.15M -3.533M 18.72M
YoY Change -276.95% -118.87%
FREE CASH FLOW
Cash From Operating Activities -$7.972M -$2.018M -$6.132M
Capital Expenditures -$424.0K -$128.0K -$98.00K
Free Cash Flow -$7.548M -$1.890M -$6.034M
YoY Change 60.54% -68.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Profit Loss
ProfitLoss
-35941000
dei Entity Central Index Key
EntityCentralIndexKey
0001828185
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34328231
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34328231
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7960458
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-169000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
98000
CY2020Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
44700000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7728000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1472000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-722000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-98000
CY2021Q3 us-gaap Liabilities
Liabilities
14100000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2165000
vacc Payments Of Transaction Costs For Redeemable Convertible Preferred Stock
PaymentsOfTransactionCostsForRedeemableConvertiblePreferredStock
3402000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
125239000
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
296000
dei Document Transition Report
DocumentTransitionReport
false
vacc Proceeds From Issuance Of Ordinary Shares Net Of Underwriters Fees
ProceedsFromIssuanceOfOrdinarySharesNetOfUnderwritersFees
102765000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
20000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7960458
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
24974000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
222733000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24954000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-6795000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-526000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
190605000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18198000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6372000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7641000
dei Entity Registrant Name
EntityRegistrantName
Vaccitech plc
dei Document Type
DocumentType
10-Q
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000025
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000025
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
34328231
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
7960458
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
344396000
dei Entity File Number
EntityFileNumber
001-40367
dei Entity Address Address Line1
EntityAddressAddressLine1
The Schrodinger Building
dei Entity Address Address Line2
EntityAddressAddressLine2
The Oxford Science Park
dei Entity Address City Or Town
EntityAddressCityOrTown
Oxford
dei Entity Address Country
EntityAddressCountry
GB
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
OX4 4GE
dei City Area Code
CityAreaCode
+44 (0)
dei Local Phone Number
LocalPhoneNumber
1865 818 808
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34852426
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
233871000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43266000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
42000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
518000
CY2021Q3 vacc Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
5382000
CY2020Q4 vacc Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
2708000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6684000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1409000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
245979000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
47901000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1033000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
629000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8780000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2136000
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
60000
CY2021Q3 us-gaap Other Assets
OtherAssets
719000
CY2021Q3 us-gaap Assets
Assets
256571000
CY2020Q4 us-gaap Assets
Assets
50666000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1337000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4667000
CY2021Q3 vacc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
4404000
CY2020Q4 vacc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2537000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
196000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
245000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
435000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
192000
CY2020Q4 us-gaap Liabilities
Liabilities
53813000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
21660000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-93472000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57720000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-9041000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-1243000
CY2021Q3 us-gaap Minority Interest
MinorityInterest
493000
CY2020Q4 us-gaap Minority Interest
MinorityInterest
391000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
242471000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-36912000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
256571000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3702000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13490000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50666000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11018000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3251000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
269000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4467000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4371000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11821000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1184000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
977000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15332000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
219000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43550000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3059000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
5555000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
4679000
us-gaap Operating Expenses
OperatingExpenses
28822000
us-gaap Operating Expenses
OperatingExpenses
14880000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7998000
CY2020Q3 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
3000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-36912000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5536000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1428000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28553000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
797000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10413000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15867533
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22697462
CY2021Q1 vacc Stock Issued During Period Value Issue Of Deferred Shares
StockIssuedDuringPeriodValueIssueOfDeferredShares
86000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7886488
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1416000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-15386000
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
5994000
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
us-gaap Profit Loss
ProfitLoss
-35941000
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
3000
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
982000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
209000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
982000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-13789000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2020Q3 us-gaap Interest Expense
InterestExpense
969000
us-gaap Interest Expense
InterestExpense
2650000
us-gaap Interest Expense
InterestExpense
969000
CY2021Q3 vacc Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
959000
CY2020Q3 vacc Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
1612000
vacc Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
2789000
vacc Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
2989000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
959000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1628000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7448000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3005000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-60000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-4570000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
200000
us-gaap Profit Loss
ProfitLoss
-35941000
us-gaap Profit Loss
ProfitLoss
-7408000
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-13000
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
42000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-189000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-157000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4557000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
158000
us-gaap Net Income Loss
NetIncomeLoss
-35752000
us-gaap Net Income Loss
NetIncomeLoss
-7251000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34843154
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7937384
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22697462
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7886488
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34843154
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-4570000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
200000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-52831000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8736000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
102765000
CY2021Q2 vacc Offering Costs
OfferingCosts
-2394000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-43744000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
68000
CY2021Q2 vacc Conversion Of Series Shares Equity
ConversionOfSeriesSharesEquity
33736000
us-gaap Profit Loss
ProfitLoss
-7408000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
281000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6473000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8167000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
268000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-7803000
CY2021Q2 vacc Conversion Of Series B Shares Equity
ConversionOfSeriesBSharesEquity
175501000
CY2021Q2 vacc Increase Decrease In Equity From Noncontrolling Interest
IncreaseDecreaseInEquityFromNoncontrollingInterest
296000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-759000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
152000
vacc Right Of Use Asset And Liability Adjustment
RightOfUseAssetAndLiabilityAdjustment
-10000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-11043000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-25000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
49000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-194000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
86000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-15985000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
249911000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3374000
CY2021Q3 vacc Offering Costs Refund
OfferingCostsRefund
229000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6473000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-4570000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
242471000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-22079000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
856000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-683000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-3951000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-25857000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
415000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-144000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-3657000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-29243000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
154000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
68000
vacc Right Of Use Asset And Liability Adjustment
RightOfUseAssetAndLiabilityAdjustment
30000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43266000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11432000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
233871000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29630000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
200000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-28821000
us-gaap Interest Paid Net
InterestPaidNet
1844000
us-gaap Profit Loss
ProfitLoss
-7408000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
150000
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
5994000
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
3000
vacc Number Of Direct And Indirect Subsidiaries
NumberOfDirectAndIndirectSubsidiaries
5
CY2021Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
309
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
209000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
982000
us-gaap Share Based Compensation
ShareBasedCompensation
12907000
us-gaap Share Based Compensation
ShareBasedCompensation
1425000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
746000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24611000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6132000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
722000
vacc Rou Assets Obtained In Exchange For Operating Lease Liabilities
RouAssetsObtainedInExchangeForOperatingLeaseLiabilities
6819000
vacc Non Cash Interest Expense On Convertible Loan Notes
NonCashInterestExpenseOnConvertibleLoanNotes
813000
vacc Non Cash Interest Expense On Convertible Loan Notes
NonCashInterestExpenseOnConvertibleLoanNotes
969000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-62000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-13789000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-486000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-927000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5494000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
862000
vacc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
2815000
vacc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
-621000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3414000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2017000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1846000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1202000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-48000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-186000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company’s actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">We have experienced and expect to continue to experience disruptions as a result of the COVID-19 pandemic that could severely impact the Company’s clinical and pre-clinical development timelines for the Company’s clinical and pre-clinical programs. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the unaudited condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements.</p>
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-4570000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
200000
us-gaap Profit Loss
ProfitLoss
-35941000
us-gaap Profit Loss
ProfitLoss
-7408000
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-13000
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
42000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-189000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-157000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4557000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
158000
us-gaap Net Income Loss
NetIncomeLoss
-35752000
us-gaap Net Income Loss
NetIncomeLoss
-7251000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34843154
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7937384
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22697462
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7886488
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1112064
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34843154
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15867533
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22697462
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7886488
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5639000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1075000
CY2021Q3 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
508000
CY2020Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
305000
CY2021Q3 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
55000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
482000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
29000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6684000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1409000
CY2021Q3 vacc Accrued Manufacturing And Clinical Expenses Current
AccruedManufacturingAndClinicalExpensesCurrent
1887000
CY2020Q4 vacc Accrued Manufacturing And Clinical Expenses Current
AccruedManufacturingAndClinicalExpensesCurrent
462000
CY2021Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
120000
CY2020Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
4000
CY2021Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1007000
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
750000
CY2021Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
407000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
250000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
629000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
806000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
354000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
265000
CY2021Q3 vacc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
4404000
CY2020Q4 vacc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2537000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3374000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
154000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12907000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1425000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
245000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
48000
vacc Contract With Customer Liability Foreign Exchange Translation
ContractWithCustomerLiabilityForeignExchangeTranslation
-1000
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
196000
CY2021Q3 vacc Number Of Square Feet Under Lease Agreement
NumberOfSquareFeetUnderLeaseAgreement
31000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8780000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2136000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
435000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
192000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7728000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1472000
us-gaap Operating Lease Payments
OperatingLeasePayments
251000
us-gaap Operating Lease Payments
OperatingLeasePayments
244000
us-gaap Operating Lease Cost
OperatingLeaseCost
372000
us-gaap Operating Lease Cost
OperatingLeaseCost
253000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
141000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
615000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
798000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1515000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1515000
CY2021Q3 vacc Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
7378000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11962000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3799000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8163000

Files In Submission

Name View Source Status
0001104659-21-137646-index-headers.html Edgar Link pending
0001104659-21-137646-index.html Edgar Link pending
0001104659-21-137646.txt Edgar Link pending
0001104659-21-137646-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vacc-20210930.xsd Edgar Link pending
vacc-20210930x10q.htm Edgar Link pending
vacc-20210930x10q_htm.xml Edgar Link completed
vacc-20210930xex10d1.htm Edgar Link pending
vacc-20210930xex10d1001.jpg Edgar Link pending
vacc-20210930xex31d1.htm Edgar Link pending
vacc-20210930xex31d2.htm Edgar Link pending
vacc-20210930xex32d1.htm Edgar Link pending
vacc-20210930_cal.xml Edgar Link unprocessable
vacc-20210930_def.xml Edgar Link unprocessable
vacc-20210930_lab.xml Edgar Link unprocessable
vacc-20210930_pre.xml Edgar Link unprocessable